National Collaborating Centre for Methods and Tools



Centre de collaboration nationale des méthodes et outils





Rapid Review: What COVID-19 testing requirements and/or recommendations do high-income countries currently have in place in healthcare and long-term care settings?

Prepared by: The National Collaborating Centre for Methods and Tools Date: July 18, 2022

Suggested Citation:

National Collaborating Centre for Methods and Tools. (2022, July 18). *Rapid Review: What COVID-19 testing requirements and/or recommendations do high-income countries currently have in place in healthcare and long-term care settings?* <u>https://nccmt.ca/pdfs/res/role-of-testing</u>

<u>Please Note</u>: An update of this review may be available. Access the most current version of this review by visiting the National Collaborating Centre for Methods and Tools COVID-19 Rapid Evidence Service at the above link.

© 2022. National Collaborating Centre for Methods and Tools, McMaster University. All rights reserved. The National Collaborating Centre for Methods and Tools (NCCMT) is hosted by McMaster University and funded by the Public Health Agency of Canada. The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada. This Rapid Review is for general information purposes only. The information provided in this Rapid Review is provided "as is" and McMaster University makes no warranties, promises and/or representations of any kind, expressed or implied, as to the nature, standard, accuracy, completeness, reliability or otherwise of the information provided in this Rapid Review, nor to the suitability or otherwise of the information to your particular circumstances. McMaster University does not accept any responsibility or liability for the accuracy, content, completeness, legality, reliability or use of the information contained in this Rapid Review. The authors declare they have no conflicts of interest to report.

Executive Summary

Background

Healthcare institutions and long-term care (LTC) facilities have implemented COVID-19 testing policies – typically as part of a broader suite of infection prevention and control (IPAC) measures – to identify and contain COVID-19 infections among staff, patients/residents, and/or visitors. Approaches to testing within healthcare and LTC settings have varied across countries, including eligibility, timing, and indication; these approaches have also evolved within countries as the pandemic itself has evolved. Many countries identify national expectations, but practice may be governed more locally, possibly resulting in significant differences between what is reported at the national level and implemented at a local level. The local implementation of testing policies may also be impacted by several known barriers and facilitators, including resource (e.g., skilled personnel and testing availability), timing (e.g., time available to test), and adherence (e.g., willingness to test) limitations.

This rapid review was produced to support public health decision makers' response to the coronavirus disease 2019 (COVID-19) pandemic. It seeks to identify, appraise, and summarize emerging research evidence to support evidence-informed decision making.

This rapid review includes a jurisdictional scan and evidence search available up to June 27, 2022, to answer the question: What COVID-19 testing requirements and/or recommendations do high-income countries currently have in place in healthcare and LTC settings?

In our review, LTC settings include nursing homes, elderly congregate care homes, assisted living facilities, and geriatric supportive care facilities.

This review also addresses the sub-question: What is the impact of testing on identifying and reducing the spread of COVID-19 in healthcare and LTC settings?

This review did not assess the effectiveness of different *types* of tests in detecting or preventing transmission of the virus that causes COVID-19.

What testing policies do high-income countries currently have in place, and what is the impact of testing on identifying and reducing the spread of COVID-19 in healthcare and LTC settings?

Key Points

- From the jurisdictional scan, we categorized testing within healthcare and LTC settings as: required (i.e., testing is mandatory), recommended (i.e., testing is encouraged, but not required), or prioritized (i.e., testing is provided and prioritized for certain groups – staff, visitors, patients/residents – but it may not be clear if/when it is required or recommended).
- Data from the jurisdictional scan demonstrated that testing is **recommended** most often, followed by **prioritized**, with testing being **required** implemented the least often. In Canada,

provincial and territorial governments **required** testing most often, followed by **prioritized** and, to a lesser extent, **recommended**.

- Four countries required testing, specifically for LTC visitors (Israel, Scotland, South Korea), resident admissions/readmissions (Scotland, Northern Ireland), and staff (Scotland).
- Eight countries (Australia, Canada, Denmark, Northern Ireland, Singapore, Sweden, Switzerland, USA) recommended testing for healthcare and LTC staff, residents/patients, and/or visitors to detect COVID-19 infection early and limit potential spread. The recommendation to test can depend on the current state of infection within a facility (e.g., during an outbreak) and surrounding area (e.g., if community transmission is high); vaccination status; presence of symptoms; and/or risk of exposure.
- Eight countries prioritized testing by providing free or reduced-priced testing for LTC staff, volunteers, visitors, and/or residents (Australia, England, Germany, Hong Kong), patients going into hospital (England, Scotland), and healthcare workers (HCW), in general (Germany, Netherlands, New Zealand, Scotland).
- In Canada, testing is required for LTC residents at admission / readmission (Alberta, Ontario, Quebec), during outbreaks (Alberta, Saskatchewan), or if symptomatic (NB). Testing is also required for LTC staff if symptomatic (NB, Ontario), asymptomatic but a close contact (Alberta, based on vaccination status), or working at multiple sites (Alberta) and LTC visitors (BC, Ontario). Certain special patient populations (e.g., transplant or NICU patients) also require testing prior to admission (Manitoba).
- Testing is **recommended** in other Canadian provinces for LTC visitors (Alberta, Saskatchewan) and suspected patient or HCW cases (Ontario, Manitoba).
- Testing is prioritized for symptomatic HCW and LTC staff and residents (Alberta, Yukon); in some cases (Quebec, NWT, PEI) this means this population is fast tracked for testing at a local health centre or testing clinics.
- Most of the testing recommendations described in the jurisdictional scan are dependent on certain contextual factors; only 3 countries (Denmark, Northern Ireland, Singapore) recommend universal testing of LTC and HCW. Some recommend expanding testing to all HCW and LTC personnel, regardless of vaccination status, if healthcare-associated transmission is suspected (e.g., during an outbreak) (US) or community transmission is high (Australia); the World Health Organization (WHO) also recommends testing under these circumstances. Others recommend testing only symptomatic HCW and LTC staff or residents (Canada, US, Sweden) or asymptomatic staff or patients with close contacts (Canada, US), again, regardless of vaccination status. Testing is not recommended among asymptomatic patients, LTC residents, and HCW who have recovered from COVID-19 in the past 90 days (Sweden, US).

- It is important to note that **national policies are likely adapted locally**. At least four countries (Canada, England, Switzerland, United States) specified that testing requirements are determined at the local (e.g., provincial/state, institutional, facility, etc.) level, creating a disconnect between national guidance and local implementation.
- Several moderate-to-high quality studies concluded that implementing testing protocols, as part of a suite of infection control measures, was associated with a lower incidence / prevalence of COVID-19 in patients and personnel (n=2), limited hospital transmission (i.e., lower transmission rates than in the community) (n=2), reduced secondary infections (n=2), and reduced mortality (n=1). Since there were no studies identified examining the impact of testing as a singular IPAC measure, it is not possible to determine the impact of any one testing approach. The certainty of the evidence is very low (GRADE); findings are likely to change as more data become available.
- At a local level, the frequency of testing, and for whom, is generally impacted by facility outbreak status and community rates of COVID-19, such that when outbreaks occur and/or community transmission is higher, the tendency for more widespread (low-threshold) testing increases.
- In LTC, one synthesis found that the frequency of LTC staff and resident testing largely depended on outbreak status or community prevalence; one synthesis recommended widespread testing in LTC settings after a case had been detected, estimating that this approach identified half of cases that would have otherwise gone undetected. Similarly, one high quality single study concluded that low-threshold (i.e., minor indications, mild symptoms) testing of LTC staff and residents prevented up to 144 secondary infections. The certainty of the evidence is very low (GRADE); findings are likely to change as more data become available.
- A small number of studies that assessed testing as part of a suite of IPAC measures, found very limited transmission among HCW in general hospital settings (n=3) and no transmission to staff associated with endoscopies (n=1), suggesting that strict adherence to IPAC measures could significantly reduce the risk of transmission. The certainty of the evidence is very low (GRADE); findings are likely to change as more data become available.
- In terms of drawbacks to asymptomatic testing, two high quality studies reported, significantly delayed time to admission for patients undergoing laparoscopic surgery for acute appendicitis (n=1) and attending the emergency department (n=1), as well as increased length of stay among those attending the emergency department (n=1). The certainty of the evidence is very low (GRADE); findings are likely to change as more data become available.
- The trade-off between expanding testing to mitigate the spread of COVID-19 with available local resources (e.g., staff time, money spent on testing), needs to be considered alongside facility outbreak status and community rates of COVID-19.

Overview of Evidence and Knowledge Gaps

- A targeted scan of jurisdictional policies returned relevant government websites, guidance documents, fact sheets, and press releases from 16 high-income countries, 10 Canadian provinces/territories, and the World Health Organization (WHO). A search of the literature returned 19 relevant studies, including five low-to-moderate quality syntheses and 14 moderate-to-high quality single studies conducted in various countries, including USA (n=6), Italy (n=2), UK (n=2), Austria (n=1), Netherlands (n=1), South Korea (n=1), Sweden (n=1). Syntheses examined evidence from LTC settings (n=2), hospitals (n=2), or both (n=1), while single studies were mostly conducted in hospital-based settings (e.g., hospital-wide or emergency, surgical, obstetric, oncology, pediatric, and mental health departments; n=13), with one study conducted in an LTC facility.
- Our jurisdictional scan did not include the provinces/territories/states of any country besides Canada, as this was beyond the scope of this review. Some countries may have been excluded if they did not have information current as of January 1, 2022 or available in English.
- There is significant heterogeneity (e.g., level of detail, varied descriptions of testing policies) and nuances (e.g., importance of local context) of the included evidence, warranting caution in interpretation of evidence.

Methods

A description of the development of the National Collaborating Centre for Methods and Tools' Rapid Evidence Service has been published (Neil-Sztramko *et al.*, 2021). The paper provides an overview of the review process with rationale for methodological decisions.

Research Questions

What COVID-19 testing requirements and/or recommendations do high-income countries currently have in place in healthcare and LTC settings?

What is the impact of testing on identifying and reducing the spread of COVID-19 in healthcare and LTC settings?

Search

On June 27, 2022, the following databases were searched using key terms PCR, test*, polic*, requirement*, hospital*, emergency department*/centre*, clinic*, long-term care, nursing home*, retirement home*, outpatient*, patient*, resident*, visitor*, support person*, admi*, staff*, physician*, doctor*, nurs* and surgeon*:

- MEDLINE database
- <u>MedRxiv preprint server</u>
- Political Science Database

A jurisdictional scan was conducted by searching government websites of high-income countries for policies current as of January 1, 2022.

A copy of the full search strategy, including all government websites searched, is available in <u>Appendix 1</u>.

Study Selection Criteria

The search results were first screened for recent guidelines and syntheses. When available, findings from syntheses and clinical practice guidelines are presented first, as these take into account the available body of evidence and, therefore, can be applied broadly to populations and settings.

Single studies were included if no syntheses were available, or if single studies were published after the search was conducted in the included syntheses. English-language, peer-reviewed sources and sources published ahead-of-print before peer review were included. Guidance documents and jurisdictional policies were included as relevant to the question. Government websites were included in the jurisdictional scan if they were available in English or could be easily translated to English (i.e., Google Translate), and were specific to testing policies current as of 2022. Surveillance and modeling sources were excluded.

| | Inclusion Criteria | Exclusion Criteria |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Population | Locations • Hospitals, including specific departments (emergency medicine, surgery, etc.) • Long-term care (LTC) • Outpatient clinics • Retirement homes • Nursing homes Populations • Patients (including admissions and readmissions) • Visitors • Staff (including physicians, nurses, etc.) • Support persons • Residents | Non-healthcare settings Recommendations, |
| | recommendations | guidelines, and data on effectiveness of COVID-19 mitigation strategies other than testing |
| Comparisons | N/A | N/A |
| Outcomes | Outcomes in the literature sources related to testing effectiveness, including, but not limited to: Rates of transmission Early identification of positive cases Cost (monetary, personnel hours, etc.) | Seroprevalence of COVID-19 Comparisons of testing methods |
| Setting | High-income countries | |

| Timeframe | Studies published Jun 1, 2021 – present (for published literature) | |
|-----------|-------------------------------------------------------------------------------------------------------------------|--|
| | Government policies, guidance, and recommendations released Jan 1, 2022 – present (for jurisdictional scan) | |

Data Extraction and Synthesis

Data relevant to the research question, such as study design, setting, location, population characteristics, interventions or exposure and outcomes were extracted when reported. We synthesized the results narratively due to the variation in methodology and outcomes for the included studies.

For the jurisdictional scan information regarding the date of release, the population of interest, and the current policies and recommendations for COVID-19 testing was extracted. If multiple websites from the same country or region contained identical information, the sources that were most recent and provided the most in-depth information were selected. A narrative description of the policy or guidance has also been provided.

Appraisal of Evidence Quality

We evaluated the quality of included evidence using critical appraisal tools as indicated by the study design below. Quality assessment was completed by one reviewer and verified by a second reviewer. Conflicts were resolved through discussion.

| Study Design | Critical Appraisal Tool |
|-----------------|------------------------------------------------------------------------|
| Synthesis | Assessing the Methodological Quality of Systematic Reviews (AMSTAR) |
| | AMSTAR 1 Tool |
| Case Control | Joanna Briggs Institute (JBI) Checklist for Case Control Studies |
| Cohort | Joanna Briggs Institute (JBI) Checklist for Cohort Studies |
| Cross-sectional | Joanna Briggs Institute (JBI) Checklist for Analytical Cross Sectional |
| | Studies |
| Quasi- | Joanna Briggs Institute (JBI) Checklist for Quasi-Experimental Studies |
| experimental | |

Completed quality assessments for each included study are available on request.

Quality assessment was not relevant for the jurisdictional sources.

The Grading of Recommendations, Assessment, Development and Evaluations (<u>GRADE</u>) (Schünemann *et al.*, 2013) approach was used to assess the certainty in the findings based on eight key domains.

In the GRADE approach to quality of evidence, **observational studies**, as included in this review, provide **low quality** evidence, and this assessment can be further reduced based on other domains:

- High risk of bias
- Inconsistency in effects
- Indirectness of interventions/outcomes
- Imprecision in effect estimate
- Publication bias

and can be upgraded based on:

- Large effect
- Dose-response relationship
- Accounting for confounding.

The overall certainty in the evidence for each outcome was determined by taking into account the characteristics of the available evidence (observational studies, some not peer-reviewed, unaccounted-for potential confounding factors, different tests and testing protocols, lack of valid comparison groups). A judgement of 'overall certainty is very low' means that the findings are very likely to change as more evidence accumulates.

Findings

Summary of Evidence Quality

This document includes data from 39 websites retrieved from a jurisdictional scan. It also includes five completed syntheses and 14 single studies for a total of 19 publications. The number of sources that addressed each question and the quality of that evidence is as follows:

| Research Questions | Evidence included | Overall certainty in evidence | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|-------------------------------|-------------------------|
| What COVID-19 testing requirements and/or recommendations do high- income countries currently have in place in healthcare and LTC settings? | Jurisdictional scan sources • 23 International • 16 Canadian | 39 | Quality not assessed |
| What is the impact of testing on identifying and reducing the spread of COVID-19 in these healthcare settings? | Syntheses Single studies | 5 14 | Very low |

Warning

Given the need to make emerging COVID-19 evidence quickly available, many emerging studies have not been peer reviewed. As such, we advise caution when using and interpreting the evidence included in this rapid review. We have provided a summary of overall certainty of the evidence to support the process of decision making. Where possible, make decisions using the highest quality evidence available.

Table 1. Jurisdictional scan – International

| Reference | Date | Document Type | Setting | Population | Testing Action | Details |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------|---------|---------------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| INTERNATIONAL | | | | | | |
| World Health Organization. (2022, March 9). <u>Country &</u> <u>technical guidance – Coronavirus</u> <u>disease (COVID-19)</u> . Technical Guidance Publications. | Mar 9, 2022 | Guidance | LTC | Residents, staff | Recommended | Studies show that testing healthcare workers (HCW) on a regular schedule is likely to identify early infection. Clear intervals for routine testing or time points are not identified but should depend on level of transmission within a facility and surrounding community, including: LTC staff should be tested as soon as a positive case is suspected or identified in either residents or staff; staff should be tested if symptomatic. During an outbreak, staff and residents should be tested regularly (e.g., weekly, if resources allow) until there are no cases in the facility. Residents should be tested on admission or re-admission in areas with community or cluster transmission if resources permit. |
| AUSTRALIA | | | | | | |
| Australian Government – Department of Health. (2022, June 10). <u>COVID-19 outbreaks in</u> <u>Australian residential aged care</u> <u>facilities</u> . | Jun 10, 2022 | National snapshot / fact sheet | LTC | Residents, staff | Prioritized | The government provides and prioritizes rapid antigen test kits for LTC staff and residents, particularly for use in high-transmission risk areas and during outbreaks (defined as one or more resident or two or more staff cases reported). |
| Council on the Ageing. (2022, March 22). <u>Industry code for</u> <u>visiting in aged care homes</u> . | Mar 22, 2022 | Industry code | LTC | Visitor | Recommended | Visitor testing rapid antigen testing on visit or PCR within 72 hrs) should be based on current level of community transmission and visitor vaccination status: Testing NOT recommended: Green (low risk of community transmission) and vaccinated (or children who are ineligible for vaccination) Testing recommended: Green (low risk) and unvaccinated Orange (moderate risk) and any vaccination status Red (high risk / outbreak) and any vaccination status |

| CANADA | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------|---------------------------------|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Government of Canada. (2022, July 5). <u>Infection prevention and</u> <u>control for COVID-19: Interim</u> <u>guidance for long-term care</u> <u>homes</u> . | Jan 25, 2022 | Interim guidance (Public Health Agency of Canada) | LTC | Residents, staff | Recommended (Additional requirements may be at the discretion of the local jurisdiction) | Consideration should be given to testing new residents prior to admission. Residents being admitted from the community or returning from another facility who develop signs or symptoms of COVID-19 within the 14-day isolation period should "promptly" be tested. Staff with recent potential risk of exposure reported prior to their shift may be required to be tested, depending on local public health guidance. |
| DENMARK | | | | | | |
| Nationalt Kommunikations Partnerskab COVID-19. (2022, July 5). <i><u>Rules and Regulations</u>.</i> | Jul 5, 2022 | Government website (joint website of Danish authorities) | Hospital, LTC | Patients, support persons; LTC staff, visitors | Recommended | From Jul 1 – Aug 15, 2022 LTC staff are encouraged to take two weekly rapid antigen test. From Aug 15, 2022 staff are encouraged to take one PCR every 14 days. Visitors of relatives 85+ years old are encouraged to take rapid antigen testing prior to visiting. Testing is recommended for patients (>12 years) and support persons without symptoms, regardless of vaccination status, prior to moving into institutions or being acutely admitted to the hospital within certain specialties. |
| ENGLAND | | | | | | |
| National Health Service. (2022, July 4). <u>Who can get a free NHS</u> <u>coronavirus (COVID-19) test</u> . | Jul 4, 2022 | Government website (National Health Service (NHS)) | Hospital, LTC | Patients, staff | Prioritized (Additional requirements may be at the discretion of the local jurisdiction) | NHS provides free at-home testing kits for high-risk groups, including patients going into hospital for a procedure (if they have received a letter from the hospital requiring them to test), patient-facing staff, and LTC staff. |
| UK Health Security Agency. (2022, May 9). <u>COVID-19 testing</u> <u>in adult social care</u> . | May 9, 2022 | Guidance (UK Health Security Agency) | LTC | Staff, residents | Prioritized | Staff and volunteers (who regularly attend a service) are eligible for free testing. |
| GERMANY | | | | | | |
| The Commissioner of the Federal Government for Culture and media. (n.d.). <u>What do you</u> <u>currently need to know about</u> <u>corona</u> . | No date | Government website (German Government Integration Commissioner) | LTC, medical institutions | Staff, visitors | Prioritized | Anyone who provides medical care or visits people in nursing homes or medical institutions are entitled to free tests. Visitors of persons over age 60 are eligible for reduced priced testing (3€). |

| HONG KONG | | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| The Government of the Hong Kong Special Administrative Region. (2022, April 30). <u>Government continues to</u> <u>provide free COVID-19 nucleic</u> <u>acid testing service for the</u> <u>elderly and targeted groups</u> . | April 30, 2022 | Press release (The Government of the Hong Kong Special Administrative Region) | LTC | Elderly (>60 years), staff and residents | Prioritized | The Food and Health Bureau offers free PCR testing for elders. Free testing also extends to staff of residential care homes for the elderly and nursing homes who are fully vaccinated. |
| ISRAEL | | | | | | |
| Israel Ministry of Health. (2022, June 24). <u>When to be tested</u> . | Jun 24, 2022 | Government website (Ministry of Health) | Assisted living facilities, LTC | Visitors | Required | Visitors to assisted living facilities or nursing homes must show proof of a negative authorized or at-home rapid antigen test, taken within 24 hrs prior to entry (children <3 years are exempt). |
| NETHERLANDS | | | | | | |
| Government of the Netherlands. (n.d.). <u>Getting tested for</u> <u>coronavirus by the GGD if you</u> <u>have symptoms</u> . | No date | Government website (Joint website of the National Government and the Ministry of Health, Welfare and Sport) | LTC, healthcare institutions | Healthcare worker, nursing home resident | Prioritized | Healthcare workers, nursing home residents and residents of other healthcare institutions are eligible for testing through municipal health services. |
| NEW ZEALAND | | | | | | |
| New Zealand Ministry of Health. (2022, June 23). <i><u>Free testing for</u></i> <u>specific groups</u> . | Jun 23, 2022 | Government website (Ministry of Health) | LTC and other residential care facilities | Healthcare workers | Prioritized | The Ministry of Health provides free rapid antigen tests for healthcare workers who work in high density vulnerable populations. |

| New Zealand Ministry of Health. (2022, May 17). <u>Testing guidance</u> . NORTHERN IRELAND | May 17, 2022 | Guidance (Government of New Zealand Ministry of Health) | LTC, hospice and other residential care facilities | Healthcare workers | Prioritized | Rapid antigen tests are provided directly to healthcare providers for testing of symptomatic workers prior to contact with vulnerable individuals (defined as those in hospital, palliative care, outpatient or residential care). Asymptomatic critical care workers working with vulnerable populations are required to perform a rapid antigen test each day prior to starting work. Vulnerable persons (e.g., those in hospital or residential care facilities) are prioritized for PCR testing. A supervised rapid antigen test will be administered with potential for a follow up PCR for definitive diagnosis. |
|--------------------------------------------------------------------------------------------------------|--------------------|---------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Department of Health of Northern Ireland. (2022, May 2). <u>Visiting with care - A Pathway</u> . | May 2, 2022 | Regional principles | LTC | Residents | Required & Recommended | Following any trip out of the care home, residents with a suspected or confirmed exposure/close contact with a COVID positive or symptomatic person are required to test (PCR; symptomatic, lateral flow devices (LFD); asymptomatic), regardless of their vaccination status. All visitors to care homes are encouraged to test prior to visiting, however it is not |
| SCOTLAND | | | | | | required. |
| National Health Service Scotland. (2022, June 16). <i>Testing</i> . | Jun 16, 2022 | Government website (NHS Inform Scotland) | health and social care | Healthcare workers, care home visitors | Prioritized | Testing remains accessible to healthcare workers in the NHS or social care settings, those going into hospital for surgery or a procedure or visiting a hospital or care home. |

| Public Health Scotland. (2022, May 31). <u>COVID-19: Information</u> and guidance for care home settings. | May 31, 2022 | Guidance (Public Health Scotland) | LTC | Healthcare workers, residents and care home visitors | Required | Testing has shifted from population-wide testing to targeted testing to support clinical care. For residents: LFD testing is required for admission. Residents returning to care homes from hospital (non-respiratory pathway) are required to have one negative PCR or LFD, preferably within 48 hours prior to discharge from hospital. Residents returning to care homes from hospital (COVID-19 recovered) are required to have one negative PCR or LFD, before discharge, preferably within 48 hours prior to discharge. Residents returning to care homes from the community (including other care homes and hospices) are required to have one negative PCR or LFD, before discharge negative PCR or LFD within 3 days prior to their admission date (when testing is not prior to admission, testing on admission is |
|--------------------------------------------------------------------------------------------------------------------|--------------------|-----------------------------------------|-----|---------------------------------------------------------------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | | | acceptable). For staff: Care home staff are required to PCR test once/week alongside LFD testing twice weekly (on workdays). New or agency staff must provide a negative PCR test prior to coming into the home. If testing is not possible, the care home manager should assess the individual risk. For visitors: Visitors are required to LFD test before visiting the care homes or twice weekly for regular visitors. |

| SINGAPORE | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------------|--------------------------------------------|----------------------------------------------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ministry of Health Singapore. (2022, April 25). <i>Further easing of</i> <i>measures for in-person visits to</i> <i>hospitals and residential care</i> <i>homes</i> . | Apr 25, 2022 | Press release (Ministry of Health Singapore) | Hospitals, residential care homes | Hospitals, residential care home visitors | Recommended | Visitors should administer a self-test prior to visiting hospitals or residential care homes. |
| Ministry of Health Singapore. (2022, February 16). <u>Resetting</u> <u>our measures to live with the</u> <u>omicron variant</u> . | Feb 16, 2022 | Press release (Ministry of Health Singapore) | Hospitals, residential care homes | Hospitals, residential care home visitors | Recommended | In the context of the Omicron wave, those coming into contact with a vulnerable person should self-test with rapid antigen test prior to leaving home that day. |
| SOUTH KOREA | | | | | | |
| Central Disaster Management Headquarters, Republic of Korea. (2022, May 26). <u>MOHW extends</u> period of face-to-face contact visits to nursing hospitals and facilities. | May 26, 2022 | Press release (Republic of Korea Ministry of Health and Welfare) | Nursing hospitals and facilities | Visitors | Required | All visitors are required to provide proof of a negative COVID-19 status via PCR or rapid antigen test prior to visiting. |
| SWEDEN | | | | | | |
| The Public Health Agency of Sweden. (2022, March 3). <u>Testing</u> <u>for COVID-19</u> . | Mar 3, 2022 | Government website (The Public Health Agency of Sweden) | Health and social care | HCWs | Recommended | HCW and those who work in social care should get tested if they develop symptoms of COVID-19. However, testing is NOT recommended if recently recovered from COVID-19 (within the previous three months). Those at risk of becoming seriously ill with COVID-19 (e.g., people in residential care) may be recommended to get tested. |
| SWITZERLAND | | | | | | |
| Swiss Confederation. (2022, June 14). <u>Coronavirus: Protect yourself</u> <u>and others</u> . | Jun 14, 2022 | Government website (Federal Office of Public Health) | Hospital or care home visitors | Visitors | Recommended | The cost of testing is covered by the federal government. Visitor regulations for hospital or care homes is set by the individual facility. |

| UNITED STATES | | | | | | |
|---------------------------------------------------------------------------------------------------------------|----------------|-----------------------------------|-----|----------------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Centers for Disease Control and Prevention. (2022, February 2). Infection Control for Nursing Homes. | Feb 2, 2022 | Government website (US CDC) | LTC | HCW and residents | Recommended | HCW who are up to date with all recommended COVID-19 vaccine doses may be exempt from expanded screening testing. For those not up to date with all recommended doses: If community transmission is high, HCW should have a viral test (e.g., rapid antigen testing or PCR) 2x/week. Infrequent workers should be tested within three days prior to their shift. If community transmission is moderate, HCW should have a viral test 1x/week. If community transmission is low, expanded testing for asymptomatic HCW, regardless of vaccination status is NOT recommended. Tests should be prioritized for symptomatic people and close contacts. Symptomatic residents, regardless of vaccination status should receive a viral test as soon as possible. Newly admitted residents, or residents who have left the facility for >24 hrs, regardless of vaccination status, should have a series of two viral tests immediately and, if negative, 5-7 days after admission. Asymptomatic residents with close contact to a confirmed case, regardless of vaccination status, should have a series of two viral testing immediately (but not earlier than 24 hrs post exposure) and, if negative, 5-7 days post exposure. Testing is NOT necessary for asymptomatic people who have recovered from SARS-CoV-2 infection in the prior 90 days; however, if testing is performed on these people, an antigen test instead of a nucleic acid amplification test (NAAT) is recommended. |

| Centres for Disease Control and Prevention. (2022, February 2). Infection Control Guidance. | Feb 2, 2022 | Government website (US CDC) | Healthcare | HCW | Recommended | Symptomatic HCWs, regardless of vaccination status should receive a viral test as soon as possible. |
|---------------------------------------------------------------------------------------------------|----------------|-----------------------------------|------------|-----|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | | | In the event of an outbreak, testing should be expanded to all HCW, regardless of vaccination or exposure status. |
| | | | | | | Asymptomatic patients with close contact to a confirmed case, regardless of vaccination status, should have a series of two viral tests immediately (but not earlier than 24 hrs post exposure) and, if negative, 5-7 days post exposure. |
| | | | | | | Testing is NOT necessary for asymptomatic patients who have recovered from SARS-CoV-2 infection in the prior 90 days; however, if testing is performed on these people, an antigen test instead of a nucleic acid amplification test (NAAT) is recommended. |
| | | | | | | Pre-procedure or pre-admission viral testing is at the discretion of the facility. |
| | | | | | | If healthcare-associated transmission is suspected or identified, facilities may consider: expanded testing of HCW and patients as determined by the distribution and number of cases throughout the facility and ability to identify close contacts. depending on testing resources available or the likelihood of healthcare-associated transmission, facilities may elect to initially expand testing only to HCW and patients on the affected units or departments, or a particular treatment schedule or shift, as opposed to the entire facility. |
| | | | | | | • If an expanded testing approach is taken and testing identifies additional infections, testing should be expanded more broadly. If possible, testing should be repeated every 3-7 days until no new cases are identified for at least 14 days. |

*HCW: healthcare worker; LTC: long-term care; PCR: polymerase chain reaction; RAT: rapid antigen testing; LFD: lateral flow device

Table 2. Jurisdictional scan – Canada

| Reference | Date | Document Type | Setting | Population | Testing Action | Details |
|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------------------|------------|---------------------|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ALBERTA | | | | | | |
| Government of Alberta. (2022, April 29). <u>COVID-19 Prevalence</u> <u>Testing and Screening – DSL,</u> <u>LTC & Hospice</u> . | Apr 29, 2022 | Guidance (Government of Alberta) | Healthcare | Residents, staff | Required Recommended Prioritized | Testing is NOT required for asymptomatic patients before triaging, providing care or before accepting a new patient who is being transferred from another site (rationale: to avoid false negatives and to prevent delay in healthcare service delivery). Symptomatic staff working in continuing and/or acute care are prioritized for testing through Alberta Health Services. In the event of outbreak at a care facility, testing is required for: • those who exhibit symptoms of COVID-19, • all residents and staff considered a close contact of a suspected or confirmed case. Any staff working at multiple sites and are NOT fully vaccinated (two-doses), must opt into the rapid testing option. |

| Government of Alberta. (2022, February). <u>Questions &</u> <u>answers: COVID-19</u> <u>requirements for licensed</u> <u>supportive living, long-term</u> <u>care and hospice settings</u> . | Feb 2022 | Guidance (Government of Alberta) | LTC, hospice and designated licensed supportive living (collectively referred to as "care facilities") | HCW, residents and visitors | Required Recommended Prioritized | Residents returning from an absence of >24 hrs, or who are asymptomatic AND fully vaccinated (defined as fully immunized plus a booster dose), and a close contact of a confirmed case should rapid antigen test on days 1, 3 and 7, of a 10 daily surveillance period as onsite capacity allows. Exemptions to the above are those who have tested positive in the previous 21 days (no further testing required). Staff who are asymptomatic and who are known close contacts of a confirmed case are managed according to their vaccination status: Fully vaccinated plus a booster dose: no rapid testing prior to work required. Fully immunized: daily rapid antigen testing is required prior to each shift for 10 days post any exposure; those who have tested positive in the previous 21 days are not required to be tested. Not fully immunized: only those who have tested positive in the previous 21 days are not restricted, all others are restricted from entering the site for 10 days. Molecular testing is prioritized by Alberta Health Services for those living and working in care facilities. All LTC and designated supportive living residents must be tested within 48 hrs of hospital discharge (prior to discharge or immediately following discharge). This applies to both new admissions and return to acute care, those who have tested positive in the previous 21 days are exempt. Visitors are encouraged to participate in rapid antigen testing prior to visiting. |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| British Columbia Ministry of Health. (2022, March 23). <u>COVID-19: Viral testing</u> guidelines for British Columbia. | Mar 23, 2022 | Guidance (BCCDC) | Healthcare | Residents, staff | Recommended | Viral testing is recommended for those at greater risk of developing severe disease, specifically those who are: hospitalized aged 70 years and older living or working in settings with others who are high-risk for severe illness (i.e., HCW in hospitals and LTC). |

| British Columbia Ministry of Health. (2022, March 18). <u>Ministry of Health – Overview</u> <u>of visitors in long-term care and</u> <u>seniors' assisted living</u> | Mar 18, 2022 | Guidance (BCCDC) | LTC, assisted living and hospice | Visitors | Required Recommended | Visitors ≥ 12 years must undergo rapid antigen testing on-site or in the community within 48 hrs prior to a visit. Visitors to a seniors assisted living building are NOT required to undergo rapid antigen testing, unless the home is part of a campus of care with LTC or where there is a common shared space with LTC, in which case testing is recommended. Visitors providing compassionate visits related to end-of-life are NOT required to undergo rapid antigen testing. Frequent visitors are not recommended to undergo rapid antigen testing more than 3x/week. Testing is NOT required for visitors who leave the facility and return the same day. |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------------|---------------------------------------------|-----------------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ΜΑΝΙΤΟΒΑ | | | | | | |
| Government of Manitoba. (2022, June 9). <u>Provincial</u> <u>guidance for COVID-19: A</u> <u>return to symptomatic testing</u> <u>infection prevention and control</u> <u>risk and response</u> . | Jun 9, 2022 | Guidance | Acute and LTC; Labour and Delivery | Patients and visitors | Required | Asymptomatic individuals, regardless of vaccine status or reported COVID-19 infection in the previous 180 days are not required to test prior to admission. Symptomatic individuals with clinical findings of COVID-19 should be tested (PCR or point-of-care test (POCT)). Surveillance asymptomatic testing is required in selected situations: persons being admitted to the Bone Marrow Transplant-Leukaemia Unit will be PCR tested upon admission. donors and recipients participating in the transplant program will be PCR tested prior to admission. mothers of infants admitted to the neonatal intensive care unit (open pod) is required to be tested upon admission. |
| NEW BRUNSWICK | | | | | | |
| New Brunswick Department of Social Development. (2022, July). <u>Living with COVID:</u> <u>Management of COVID-19 for</u> <u>New Brunswick long term care</u> <u>homes</u> . | July, 2022 | Guidance | LTC | Residents and staff | Required Recommended | Point-of-care testing (POCT) is required for symptomatic residents and staff. Secondary PCR testing is recommended if initial POCT is positive, and resident or staff is asymptomatic. Re-testing (PCR/POCT) is recommended for those who previously tested positive: <30 days, no additional testing is recommended unless known risk of exposure and reinfection is suspected between 30 and 90 days for those with worsening symptoms is more than 90 days, if the individual is symptomatic. |

| NORTHWEST TERRITORIES | | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------------------------------------|------------|-----------------------------------------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Northwest Territories Health and Social Services Authority. (2022, April 25). <u>COVID-19</u> <u>public testing guidance</u> . ONTARIO | Apr 25, 2022 | Guidance | Healthcare | Residents and HCW | Prioritized | Symptomatic individuals who are residents or staff of a congregate living facility are prioritized for testing at a local health centre or testing centre. |
| Government of Ontario. (2022, June 28). <u>COVID-19 guidance</u> <u>document for long-term care</u> <u>homes in Ontario</u> | Jun 28, 2022 | Guidance (Ontario of Ministry of Health) | LTC | Visitors, Staff and support staff | Required | LTC staff are required to rapid antigen test at least two times per week, on separate days, if they are up to date with recommended COVID-19 doses. Those who are not up to date with current doses are required to rapid antigen test at least 3 times per week, on separate days. Staff should not provide direct care to a resident until a negative result is received. |
| | | | | | | All visitors and support workers entering a LTC must provide a negative antigen test taken at the LTC on that day or demonstrate proof of negative test result from an antigen test or PCR test taken on the same day or the day prior to the visit (those who enter on two consecutive days within a seven-day period may enter without requiring a second negative test. Those who have had a prior confirmed COVID-19 infection in the past 90 days do not perform screening or testing until the 90 th day from the start of their confirmed infection. |
| Ontario Ministry of Health. (2022, June 11). <u>COVID-19</u> <u>guidance: Acute care</u> . | Jun 11, 2022 | Guidance (Ontario Ministry of Health) | Acute care | Residents and staff | Required | Suspected patients and/or staff cases should be tested with a PCR test, rapid molecular test, or a rapid antigen test. |
| Ontario Ministry of Health. (2022, June 11). <u>COVID-19</u> <u>guidance: Long-term care</u> <u>homes and retirement homes</u> <u>for public health units</u> . | Jun 11, 2022 | Guidance (Ontario Ministry of Health) | LTC | Residents | Required | Residents being transferred from another LTC, retirement home, or healthcare facility that is not experiencing a COVID-19 outbreak at the time of transfer are required to take a molecular test on day 5, post transfer. The resident is not required to isolate if they pass initial screening and are asymptomatic. Residents coming from the community are required to take a PCR test prior to admission (i.e., within 24 hours), or on arrival (i.e., day 0) and a second PCR test on or after day 5. |
| PRINCE EDWARD ISLAND | | | | | | |
| Government of Prince Edward Island. (2022, June 7). <u>COVID-19</u> <u>close contacts</u> . | Jun 7, 2022 | Website (Government of Prince Edward Island) | LTC | Residents, staff | Prioritized | Those who live or work in vulnerable settings (i.e., HCW, LTC staff and residents) are prioritized for testing at a community testing clinic. |
| Health PEI. (2022, January 5). <u>Fast pass priority COVID-19</u> <u>testing available for staff</u> . | Jan 5, 2022 | Website (Health PEI) | Healthcare | HCW | Prioritized | Health system employees are eligible for priority testing through COVID-19 testing clinics if they have an upcoming shift and require testing beforehand or are symptomatic and have not been diagnosed with COVID-19. |

| QUÉBEC | | | | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------------------------------------------------------|---------------------------------------------------------|--------------------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Government of Québec. (2022, May 30). <u><i>Get a COVID-19 test</i></u> . | May 30, 2022 | Website (Government of Quebec) | Health care, LTC, retirement, nursing homes | HCW, residents | Prioritized | Heath, social services workers and clients who receive, or will receive, healthcare and social services in a healthcare or residential facility (e.g., continuous assistance residences, private senior's homes, residential centres or residential long-term care centres, respite homes, birthing centres, palliative care hospices, residential settings) are prioritized for PCR testing at screening clinics. |
| Government of Québec. (2022, May 4). <u>Instructions regarding</u> <u>clients' or residents' admission</u> <u>or return to a residence or</u> <u>rehabilitation centre</u> . | May 4, 2022 | Website (Government of Quebec) | Residential centre | Residents | Required | Residents being admitted or returning to a residential centre who are asymptomatic and have been in close contact with someone who has had COVID-19 or had a high-risk exposure in the community to a person who has COVID-19 must do a screening test (test type not reported (NR)). |
| SASKATCHEWAN | | | | | | |
| Saskatchewan Health Authority. (2022, June 20). <u>Saskatchewan</u> <u>Health Authority COVID-19</u> <u>outbreak guidance for long</u> <u>term care homes</u> . | Jun 20, 2022 | Outbreak Guidance (Saskatchewan Health Authority) | LTC | HCW, residents, visitors | Required | *These are outbreak guidelines and may not apply during non-outbreak conditions. Staff testing: staff testing can occur via peer-to-peer or point-care-testing; staff may access testing in the community if they are not scheduled to work for the next 2-3 days; staff may continue to work while awaiting results provided they pass the HCW screening tool; staff who are considered COVID-19 recovered do not need to be tested if it has been ≤ 90 days from when they first tested positive. |
| | | | | | | Resident testing: residents who are considered COVID-19 recovered do not need to be tested if it has been ≤ 90 days from when they first tested positive; residents who have been tested within 48 hours do not need to be re-tested unless they develop symptoms. Visitor testing: where capacity/feasibility exists, POCT of essential family/support persons, visitors and staff should occur immediately upon entering the home if they have not been tested in the previous 7 days. |

| YUKON | | | | | | |
|----------------------------------------|--------|-------------|-------------|------------|-------------|--------------------------------------------------------------------------------------------|
| Yukon Communicable Disease | Jun 8, | Guidance | Healthcare, | HCW, | Prioritized | Symptomatic individuals who are residential or congregate setting residents or staff, |
| Control. (2022, June 8). <u>COVID-</u> | 2022 | (Government | LTC and | residents, | | patients in acute healthcare settings and frontline HCW delivering direct patient care are |
| <u>19 testing regulations –</u> | | of Yukon) | residential | patients | | prioritized for PCR testing. |
| Whitehorse and rural Yukon. | | | care | | | |
| | | | | | | Testing is not recommended for recently recovered COVID-19 cases in the first 45 days |
| | | | | | | following initial positive lab test. |

*HCW: healthcare worker; LTC: long-term care; POCT: point-of-care testing; PCR: polymerase chain reaction

Table 3: Syntheses

| Reference | Date Released | Population, Setting | Description of Included Studies | Additional mitigation measures | Summary of Findings | Quality Rating: Synthesis | Quality Rating: Included Studies |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------------------------------|
| Mei, Y., Guo, X., Chen, Z., & Chen, Y. (2022). <u>An</u> <u>effective mechanism for</u> <u>the early detection and</u> <u>containment of</u> <u>healthcare worker</u> <u>infections in the setting</u> <u>of the COVID-19</u> <u>pandemic: a systematic</u> <u>review and meta-</u> <u>synthesis</u> . <i>Int J Environ</i> <i>Res Public Health</i> , <i>19</i> (10), 5943. | May 13, 2022 (Search conducted Apr 2020 - Mar 2022) | Healthcare workers US, UK, Singapore, Italy, China, Malaysia, Germany, Belgium, Netherland, Turkey, Australia, Philippines, Brazil | This systematic review included 38 studies: 28 addressed testing. • 27 observational • 1 experimental | Additional IPAC measures include: • syndromic surveillance • contacting tracing • exposure management | Some studies advocate for HCWs to be given low-threshold access to testing, with debate on whether this applies to asymptomatic HCWs. Pros: early detection, reduce risk of nosocomial transmission, potential cost savings (e.g., one study found that compared to quarantining, antigen testing HCWs every other day reduced total cost by 87%). Cons: scarce time/resources, symptoms are best predictors so unnecessary if sufficient PPE and invention prevention and control measures in place, false negatives. The authors conclude that one effective strategy, in line with Centers for Disease Control (CDC) guidelines on testing sensitivity and specificity, includes: Provide HCWs with a known exposure, antigen tests* If positive, consider infected. If negative, confirm with PCR test. (*Antigen tests have shorter testing time, independent application/interpretation, comparable specificity to PCR (according to CDC guideline, i.e., false positive results are unlikely), but lower sensitivity.) | Moderate | Low to moderate |

| Hashim, N., Mahdy, Z.A., Abdul Rahman, R., Kalok, A., & Sutan, R. (2022). <u>Universal</u> <u>Testing Policy for</u> | Feb 8, 2022 (Search dates not reported) | Obstetrics, worldwide | This systematic review includes 34 observational studies, all addressed testing. | None reported | This systematic review reports the prevalence of worldwide <i>pre-admission universal testing</i> (i.e., all tested with at-home or point-of-care rapid antigen test, regardless of symptoms or exposures) of pregnant women presenting to labour and delivery admission units. | Moderate | Moderate |
|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------|----------------------------------------------------------------------------------------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|----------|
| COVID-19 in Pregnancy: A Systematic <u>Review</u> . Frontiers in public health, 10, 588269. | | | | | On average, 5.3% of the 19,958 women included tested positive, with positivity rates ranging from 0.4% (17/3,906) to 27.0% (137/370): Of those who tested positive on admission, 260/19,958 (1.3%) were asymptomatic. Of those who tested positive in total, 75.5% were asymptomatic compared to 24.5% symptomatic. 13,165/19,958 (66.0%) of the total population tested were from the United States, one of the countries with the highest number of populations affected by the disease. Policy implementation was highest in New York, Italy, Spain and Portugal. | | |

| Bertini, L., Bogen- Johnston, L., Middleton, J., Wood, W., Sadhwani, S., Forder, J., Cassell, J.A. (2021). <u>COVID-19</u> <u>management in social</u> <u>care in England: a</u> <u>systematic review of</u> <u>changing policies and</u> <u>newspaper reported</u> <u>staff perspectives</u> . <i>Preprint</i> . | Nov 21, 2021 National guidance for social care search (29 Jul – 28 Oct 2020) Newspaper coverage of infection control issues in social care (27 Jul – 10 Sept 2020) | LTC / social care, UK | This systematic review includes 15 guidance documents: 1 addressed testing. This systematic review includes 24 newspaper articles: 10 addressed testing. | Additional IPAC measures include: • PPE • Distancing • Contact between workers • Self-isolation | This systematic review integrated a comparison of government guidance documents and newspaper articles of infection control issues in social care homes. The review of the guidance documents reports the government was looking to increase staff testing from the current policy requiring asymptomatic staff have ongoing access to individual testing (increased capacity not stated). In the event of a suspected outbreak, Public Health England provides testing to support outbreak control. Review of the newspaper articles reveals that care staff are required to test weekly, while residents undergo monthly testing. Critiques of this strategy were critical, noting that testing was implemented too late and due to industry pressure. Industry executives criticized gaps in the staff testing system, noting that staff have a variety of movements during the week after they have been tested which could lead to asymptomatic infection. Staff highlighted the pressure to receive patients without testing coming from hospitals and noted a lack of clear guidance on | Low PREPRINT NOT PEER REVIEWED | Not assessed |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-----------------|
| Egunsola, O., Farkas, B., Flanagan, J., Salmon, C., Mastikhina, L., Clement, F. (2021). <u>Surveillance of COVID-</u> <u>19 in a Vaccinated</u> <u>Population: A Rapid</u> <u>Literature Review</u> . <i>Preprint</i> . | Nov 8, 2021 Search conducted Jun 14, 2021 | Heathcare, LCT worldwide | This rapid review includes 33 studies: 21 addressed testing in healthcare and LTC. • 21 observational | None reported | return-to-work policies post infection. This rapid review explored COVID-19 surveillance in vaccinated populations, including healthcare and LTC settings. The findings in healthcare settings highlighted the differences in strategies and tests used. The most common test reported was RT-PCR, but some studies reported using rapid antigen test and testing with RT-PCR as a confirmation test. Testing strategies included routine post-exposure universal testing for staff and periodic surveillance testing. All studies identified breakthrough cases among vaccinated individuals highlighting the need for continued testing. The findings for LTC facilities found the frequency of testing largely depended on outbreak status of the facility or surrounding community prevalence. Reviews noted testing of both residents and staff. | Moderate PREPRINT NOT PEER REVIEWED | Not assessed |

| Giri, S., Chenn, L.M., & Romero-Ortuno, R. (2021). <u>Nursing homes</u> <u>during the COVID-19</u> <u>pandemic: a scoping</u> | Jun 16, 2021 (Search conducted Mar 1, 2020 | LTC, worldwide | This scoping review includes 76 studies: 10 observational studies addressed | Additional IPAC measures include: • Isolation • Cohorting • Staff protection | This scoping review identified widespread testing as a strategy to mitigate the impact of COVID-19 in nursing homes, noting the evolution of testing strategies throughout the pandemic; initially from those indicated to widespread testing. Widespread testing aided in the identification of cases as | Low | Not assessed |
|-------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|-------------------|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------------|
| review of challenges and responses. <i>European geriatric medicine, 12</i> (6), 1127– 1136. | – Jan 31, 2021) | | testing. | and support Technology in care | prevalence of typical COVID-19 symptoms was much lower than expected in LTC homes resulting in significant failure to identify infection in residents. It is estimated that the shift to widespread testing identified up to 50% of COVID-19 cases that would have otherwise gone undetected. Studies reported a decrease in point case prevalence from 35% | | |
| | | | | | Studies reported a decrease in point case prevalence non 35% down to 18% after implementation. Widespread testing was recommended after case detection; delays in testing were associated with the risk of larger outbreaks. | | |

*IPAC: infection prevention and control; HCW: healthcare worker; PPE: person protective equipment; CDC: Centers for Disease Control; LTC: long-term care; RT-PCR: reverse transcriptase polymerase chain reaction

Table 4: Single Studies

| Reference | Date Released | Study Design | Population, Setting | Participants, COVID strain | IPAC & Screening Measures | Summary of Findings | Quality Rating: |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|----------------------------|-----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Diekmann, P.R., O'Neill, O.R., Floyd, E.R., Meinke, L.C., Lehman-Lane, J., Uzlik, R.M., & Stone McGaver, R. (2022). Orthopedic Surgery in Ambulatory Surgery Centers During the COVID-19 Pandemic: Low Incidence of Infection Among Patients, Surgeons, and Staff. Cureus, 14(4), e24247. | Apr 18, 2022 | Quasi- experime ntal | Surgical patients and personnel Orthopedic surgery practice Minnesota, United States | n=13,115 patients • mean age: 52(SD±17.4) • 16,491/23,11 5 (53.6%) women n=642 personnel Apr 28 -Dec 31, 2020 (wild-type/ Alpha VOC) | Staff procedure: Daily online assessment prior to start of shift Bi-weekly PCR testing Self-monitoring Emergency patient procedure: Test prior to surgery (test type NR) Scheduled patient procedure: RT-PCR test prior to surgery (≤96 hrs) Self-quarantine between test and procedure Symptom screening in lobby upon arrival Visitor restrictions; exemption for minors (<18 years) Designated drivers for day surgery patients were connected with patients outside of the building upon discharge. | During the study period, 12,115 patients representing 13,304 procedures were tested for COVID-19: 70/12,115 (0.6%) tested positive 51 of the positive cases were identified in Nov and Dec of 2020 when the Alpha VOC was quickly becoming the dominant strain of COVID-19 in the US. During the study period, 642 personnel were tested for COVID-19 (8,594 tests). Each staff was tested an average of 13.1 times: 41/642 (6.4%) tested positive. The authors conclude that based on their finding, the infection control procedures implemented were associated with a low incidence of COVID-19 in patients and personnel. | Moderate |

| Fong, D., Mair, M.J., | Sep 28, | Cohort | Oncology | n=719 | Staff measures: | During the study period, defined as the second wave of COVID-19, | High |
|------------------------------------|---------|--------|--------------|---------------------------------|---------------------------------------|-------------------------------------------------------------------|------|
| Lanthaler, F., Alber, M., & | 2021 | | outpatients | median age: | Separated by Home | 719 patients were treated representing 4754 patient visits and | |
| Mitterer, M. (2022). | | | | 64 (IQR: 28- | Office (no crossover | 1454 treatments. 106/719 (14.7%) tested positive for COVID-19. | |
| Mobility as a driver of | | | Franz | 88) | between facilities) | | |
| severe acute respiratory | | | Tappeiner | • 51/106 | | Compared to the first wave, the case positivity during the study | |
| syndrome coronavirus 2 | | | Hospital | (48.1%) | Outpatient measures: | period (second wave) was ~20 times higher (0.8% vs. 14.7%), | |
| in cancer patients during | | | Merano | women | Provided tele- | p<0.001. | |
| the second coronavirus | | | | | medicine on a case | • The positivity rate of outpatients was significantly lower than | |
| disease 2019 pandemic | | | South Tyrol, | Oct 19, 2020 - | by case basis | the community, resulting in a reduction of 58.5% of new | |
| wave. International | | | Italy | Feb 28, 2021 | RT-PCR testing 2 | positive cases. | |
| <i>journal of cancer, 150</i> (3), | | | | | days prior to any | • The death rate of outpatients was significantly higher than in | |
| 431–439. | | | | (wild-type and | intravenous or | the community (7/106 (6.6%) vs. 731/46,421 (1.6%)), p<0.001. | |
| | | | | Alpha VOC) | subcutaneous | | |
| | | | | | treatment | Among all the positive patients, infection was determined to be | |
| | | | | | | community acquired and not in-hospital infection according to | |
| | | | | | *During this time local | contact tracing by local authorities, p<0.001. | |
| | | | | | restrictions were | | |
| | | | | | relaxed. | | |

| Geeraedts, F., Luttje, M., Mar 16, Case LTC residents n=19,087 National guidelines: For two weeks prior to the peak of the | first wave of the epidemic, | High |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------|------|
| Visschedijk, J., van 2022 control and HCW • 13,438 HCW • HCW with mild the region of Twente adopted a diverg | | 5 |
| Hattem, M., Hasper, H.J., • 5,649 symptoms without strategy for staff and residents of LTC | | |
| Kohnen, R., Al Naiemi, Twente GGD residents fever can continue | | |
| N. (2022). Low-Threshold to work without During the study period, 144/13,348 (1. | .08%) HCW and 96/5,649 | |
| Testing for SARS-CoV-2 Twente Mar 3 – Apr 9, being tested, while (1.69%) residents tested positive for CO | | |
| (COVID-19) in Long-Term Region, 2020 HCW with a fever all positive cases in the region. | | |
| Care Facilities Early in the Overjissel, (wild-type) have to stay home | | |
| First Pandemic Wave, the Netherlands without being tested In the following two weeks the percent | tage of COVID-19 related | |
| Twente Region, the deaths/inhabitant in the region was 0.0 | | |
| Netherlands: A Possible resolved within 24 in other parts of the province. | | |
| Factor in Reducing hrs, then HCW could | | |
| Morbidity and return to work) Excess mortality rate in the Twente reg | gion (8%) was 62-89% lower | |
| Mortality. Journal of • Residents to be RT- than other parts of the province where | e low-threshold guidelines | |
| applied gerontology, PCR tested only in were not adopted (values NR). | | |
| 7334648221093050. the presence of | | |
| fever National R₀ during the study period wa | | |
| Hospital discharge 0.7 – 1.0, resulting in an estimated 101 | - | |
| after 1 day prevented due to the adoption of low-t | threshold testing. | |
| symptom-free with | | |
| no testing. | | |
| Twente guidelines: | | |
| HCW with minimal | | |
| symptoms in the | | |
| absence of fever | | |
| had to stop working | | |
| and immediately | | |
| RT-PCR test | | |
| (referred to as "low | | |
| threshold testing") | | |
| Residents to be | | |
| tested at the first | | |
| sign of any | | |
| symptom | | |
| Hospital discharge | | |
| after 3 days | | |
| symptom free with | | |
| the possibility of | | |
| testing. | | |
| | | |

| Liu, K.Y., Kulatilake, A., | Mar 8, | Quasi- | Mental health | n=91 | Reference period (Mar | Compared to the reference period, the study period prevalence of | High |
|------------------------------------------------|--------|----------|--------------------|----------------|-----------------------|---------------------------------------------------------------------|------|
| Kalafatis, C., Smith, G., | 2022 | experime | patients | • mean age: | 1 – Apr 30, 2020) | COVID-19 was significantly lower; $91/358$ (25% 95% Cl = 21,30) vs. | |
| King, J.D., Serra-Mestres, | | ntal | (older in- | 77(SD±7.2) | Limited and delayed | 131/344 (38% 95% CI = 33,43) p<0.001. | |
| J., Livingston, G. | | | patients ≥ 65 | • 52/91 (57%) | testing | | |
| (2022). <u>Infection control</u> | | | and those | women | Limited availability | Of all new admissions in the study period 31/127 (24%) who tested | |
| and the prevalence, | | | with | • 17/89 (19%) | of PPE | positive, the median number of days between admission and first | |
| management and | | | dementia) | Black | 01112 | test was 0 [IQR: 0, 1] compared to new admissions in the reference | |
| outcomes of SARS-CoV-2 | | | domonta, | Caribbean, | Study period (Dec 14, | period who experienced a delay of 6 days [IQR: 4.7, 7]. | |
| infections in mental | | | London | African | 2020 – Feb 15, 2021) | | |
| health wards in London, | | | National | British | Immediate access to | | |
| UK: lessons learned from | | | Health | • 6/89 (7%) | PCR tests | | |
| wave 1 to wave | | | Service | Asian or | Unlimited access to | | |
| <u>2</u> . <i>BJPsych open</i> , <i>8</i> (2), | | | mental health | Asian British | PPE | | |
| e63. | | | trusts | • 3/89 (3%) | Testing prior to | | |
| | | | | Mixed or | arrival for transfer | | |
| | | | London, | other | patients | | |
| | | | United | | PCR tests for pre- | | |
| | | | Kingdom | Dec 2020 – Feb | admission | | |
| | | | U | 2021 | screening for | | |
| | | | | (Alpha VOC) | symptomatic staff | | |
| | | | | | PCR or LFD testing | | |
| | | | | compared to | for asymptomatic | | |
| | | | | reference | staff 1-2x/week | | |
| | | | | period Mar 1 – | Visitor restrictions | | |
| | | | | Apr 31, 2020 | | | |
| | | | | (wild-type) | | | |

| Moyer, S., Aktay, S., & | Apr 28, | Cohort | Pediatric | n=1200 | Endoscopy intake | During the study period, the volume of endoscopy procedures | Moderate |
|----------------------------------|---------|--------|---------------|---------------|----------------------------------------|----------------------------------------------------------------------|----------|
| Blanchard, S. (2022). <u>The</u> | 2022 | | patients | | procedure: | was drastically reduced due to hospital policy (elective procedures | |
| COVID-19 Pandemic | | | (aged 1-21 | Mar 1, 2019 – | RT-PCR testing 48- | were postponed) and patient cancellations due to COVID infection. | |
| Impact on Pediatric | | | years) | Mar 1, 2020 | 72 hrs prior to | This resulted in fewer than 10 monthly procedures completed in | |
| Endoscopies in a Single | | | | (wild-type) | procedure | Mar-Apr 2020 compared to 52 average monthly procedures in | |
| Center. Global pediatric | | | University of | | Screening questions | 2019. | |
| health, 9, | | | Maryland | | completed over the | | |
| 2333794X221100948. | | | | | phone 2-3 days | Pre-procedure testing resulted in 1% total patients testing positive | |
| | | | Maryland, | | prior to procedure | for COVID-19 (values NR). None of the endoscopists or trainees | |
| | | | USA | | (anyone with a | tested positive during the same time period. | |
| | | | | | positive screening | 5 5 5 5 5 5 F 5 5 5 5 F 5 5 5 5 5 5 5 5 | |
| | | | | | answer was | Procedure volumes in the ensuing months of 2020 returned to | |
| | | | | | removed from the | those in the pre-pandemic period. | |
| | | | | | schedule) | | |
| | | | | | • PPE (N95 mask, face | | |
| | | | | | shield, gloves, fully | | |
| | | | | | body water resistant | | |
| | | | | | isolation gown and | | |
| | | | | | hairnet) | | |
| | | | | | | | |
| | | | | | Family member | | |
| | | | | | restrictions | | |
| | | | | | Patient and family | | |
| | | | | | masking | | |

| Rhee, C., Baker, M.A., & | Jun 16, | Cross- | Hospital | n = 23 | All hospital mitigation | Overall, 21/23 (91%) of hospitals surveyed practiced universal | Moderate |
|-----------------------------|---------|-----------|--------------|-----------------|------------------------------------------|-----------------------------------------------------------------------------------|----------|
| Klompas, M. (2022). | 2022 | sectional | epidemiologi | | measures: | testing of patients on admission. 2/23 (9%) sites restricted testing | |
| Survey of coronavirus | | | sts | Feb 15 – Mar 3, | Universal masking | to only symptomatic/exposed of high-risk patients. | |
| disease 2019 (COVID-19) | | | | 2022 | PPE (e.g., eye | | |
| infection control policies | | | Nation-wide | (Omicron VOC) | protection, gown | • 7/23 (30%) hospitals administered at least 1 post-admission test | |
| at leading US academic | | | | | and glove) | to detect virus that may have been missed by the admission | |
| hospitals in the context of | | | USA | | | test. Days to second test ranged from 3 to 7 days. | |
| the initial pandemic surge | | | | | Some hospital | | |
| of the severe acute | | | | | mitigation measures: | 6/23 (26%) hospitals reported ongoing surveillance testing on | |
| respiratory coronavirus | | | | | Dedicated COVID-19 | covid negative patients; days to second test ranged from 4-7 | |
| virus 2 (SARS-CoV-2) | | | | | units | days. | |
| omicron variant. Infection | | | | | Air purifiers | | |
| control and hospital | | | | | Universal testing of | 5/23 (22%) hospitals reported tailored strategies including | |
| epidemiology, 1–7. | | | | | patients on | repeated surveillance testing at 3-day intervals for 14 days for | |
| | | | | | admission | specific high-risk groups (e.g., those undergoing aerosol- | |
| | | | | | Regular testing of | generating procedures (n=2), pre-procedure testing after day 7 | |
| | | | | | unvaccinated | (n=1), repeated testing for patients in congregate units (n=1) bi- | |
| | | | | | employees | weekly testing for patients receiving nebulizers (n=1). | |
| | | | | | Mandatory testing | | |
| | | | | | of all employees, | Testing type differed based on symptom status; in asymptomatic | |
| | | | | | regardless of | patients: | |
| | | | | | vaccination status. | • 13/23 (57%) used nasopharyngeal swabs | |
| | | | | | | • 8/23 (35%) used anterior nasal swabs | |
| | | | | | | • 2/23 (9%) used midturbinate swabs | |
| | | | | | | No hospitals reported using saliva tests | |
| | | | | | | In symptomatic patients: | |
| | | | | | | • 18/23 (78%) used nasopharyngeal swabs | |
| | | | | | | • 4/23 (17%) used anterior nasal swabs | |
| | | | | | | No hospitals reported using saliva tests | |
| | | | | | | | |
| | | | | | | The role of testing was mixed in clearing positive patients; 8/23 | |
| | | | | | | (35%) relied on time-based criteria; 2/23 (9%) used test-based | |
| | | | | | | criteria; 12/23 (52%) used time-based criteria supplemented with | |
| | | | | | | testing for risk patients with immunocompromising conditions. | |
| | | | | | | Overall, 1/23 (4%) hospitals required mandatory weekly employee | |
| | | | | | | testing (regardless of vaccination status); this was time limited to | |
| | | | | | | surge due to the omicron VOC | |
| | | | | | | 5/23 (22%) required regular testing of unvaccinated employees | |
| | 1 | | | | | • 5/25 (22 /0) required regular testing of unvaccinated employees | |

| | | | | | | 18/23 (78%) did not have a mandatory surveillance testing program; employees required a test if they developed new symptoms or had a known exposure. Of this 18, 13 (72%) allowed electing testing at the employee's discretion. | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|---------------------|----------------------------------------------------|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Sangal, R. B., Peaper, D. R., Rothenberg, C., Landry, M. L., Sussman, L. S., Martinello, R. A., Ulrich, A., & Venkatesh, A. K. (2022). <u>Universal</u> <u>SARS-CoV-2 Testing of</u> <u>Emergency Department</u> <u>Admissions Increases</u> <u>Emergency Department</u> <u>Length of Stay</u> . <i>Annals of</i> <i>emergency medicine</i> , <i>79</i> (2), 182–186. | Feb 7, 2022 | Cross- sectional | Emergency department Health system USA | n= 70,856 Mar 15 – Sep 30, 2020 | Health system is made up of 3 distinct sites. Patients were transferred between sites based on bed availability. Additional IPAC measures NR. | From Mar 15 – Apr 24, 2020, hospital policy restricted COVID-19 testing to only those patients under investigation with lower respiratory tract infection symptoms, fever or clinical suspicion of COVID-19. From Apr 24 onward, a universal testing policy was adopted for all ED admissions. During the study period, 70,856 patients accessed the ED: 11,541/70,856 (16.3%) prior to universal testing policy; 3,910/11,541 (33.9%) were admitted 59,315/70,856 (83.7%) post universal testing policy; 18,311 (30.9%) were admitted. For those admitted to the ED, the universal testing policy was associated with: 1.89 hrs increase in ED admitted length of stay (95% CI = 1.39, 2.38) representing a 24% increase in admission length of stay 0.19 hr increase in discharge length of the stay (95% CI = 0.069, 0.3) 1.58 hrs increase in ED boarding length of stay (95% CI = 1.15,2.01) In times of high community transmission (39.7%), the lowest number needed to treat was 2.5 patients/week to identify 1 positive case. In times of low community transmission (0.5%), the number needed to test exceeded 170 patients/week being tested to identify 1 positive case. | High |

| Benoni, R., Campagna, I., Panunzi, S., Varalta, M. | May 19, 2021 | Cohort | HCW | n=6455 | University health surveillance screening | During the study period, 6,455 HCW were tested for COVID-19 through the HSP; 248/6,455 (3.8%) tested positive (95% CI = | High |
|-------------------------------------------------------|-----------------|--------|---------------|---------------------------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|----------|
| S., Salandini, G., De | _ | | University | Feb 29, 2020 – | (HSP) programme: | 3.4,4.3). Of those positive 121/248 (49%) were asymptomatic: | |
| Mattia, G., Bovo, C. | | | Hospital of | May 18, 2020 | High risk wards | • There were no significant differences between those who tested | |
| (2021). Estimating COVID- | | | Verona | (wild-type) | (e.g., ICU, infectious | positive or negative with respect to age, sex or ward related | |
| <u>19 recovery time in a</u> | | | | (| disease, respiratory | risk; | |
| cohort of Italian | | | Veneto | | disease, COVID-19 | • Symptomatic HCW were significantly older (mean 48.2) than | |
| healthcare workers who | | | Region, Italy | | units) RT-PCR tested | asymptomatic HCW (mean 39.8), p<0.001. | |
| underwent surveillance | | | nogion, nary | | ever 10 days | | |
| swab testing. Public | | | | | Clinical staff RT-PCT | 127/248 (87.5%) positive cases were initially referred for HSP | |
| <i>health, 196</i> , 52–58. | | | | | tested every 20 days | testing after close contact with a positive patient. | |
| <i>neann, 190,</i> 52–58. | | | | | Staff and | lesting after close contact with a positive patient. | |
| | | | | | | | |
| | | | | | administration RT- | 31/248 (12.5%) positive cases were identified through routine HSP | |
| | | | | | PCR tested every 30 | screening. | |
| | | | | | days | | |
| | | | | | | Return to work testing (time from initial positive test to second | |
| | | | | | | consecutive negative test) indicated a median recovery time of 21 | |
| | | | | | | days (95% Cl = 15.5, 30.5). | |
| Berger, J. M., Gansterer, | Aug 19, | Case | Cancer | n= 1,557 | Staff measures: | During the study period, only asymptomatic oncology outpatients | Moderate |
| M., Trutschnig, W., | 2021 | report | outpatients | median age: | Staffing cohorts | were permitted access to the department. As per institutional | |
| Bathke, A. C., Strassl, R., | | | | 63 (IQR: 18- | Separate access for | policy, these patients underwent bi-weekly PT-RCT testing; | |
| Lamm, W., Raderer, M., | | | Oncology | 93) | patients with | 23/1,577 (1.46%) tested positive. | |
| Preusser, M., & Berghoff, | | | centre | • 913/1,577 | structured triage | | |
| A. S. (2021). <u>SARS-CoV-2</u> | | | | (57.9%) | with a HCW | Compared to the first wave, the detection rate in the second wave | |
| screening in cancer | | | Medical | women | PPE | significantly increased; 1.5% (95% CI = 1.0, 2.2) vs. 0.4% (95% CI = | |
| outpatients during the | | | University of | | Hygiene | 0.1,1.0%); with an odsds ratio (OR) = 3.9 (95% CI = 1.5, 10.1), | |
| second wave of the | | | Vienna, | Oct 1 – Nov 30, | recommendations | p<0.005. This is comparable to community positivity rates for the | |
| COVID-19 pandemic : | | | Austria | 2020 | | same time period comparison; $OR = 4.0$ (95% $CI = 4.0$, 4.1), | |
| Conclusions for crisis | | | | (wild-type and | Patient measures: | p<0.001. | |
| response at a high- | | | | Alpha VOC) | Masks and | | |
| volume oncology | | | | | protective gear | Patients undergoing active anti-cancer treatment (172/960; 17.9% | |
| <u>center</u> . Wiener klinische | | | | | | not tested) were more likely to have been tested than patients in | |
| Wochenschrift, 133(17- | | | | | test all patients in | follow-up or best supportive care (326/617; 52.8% not tested p< | |
| , . | | | | | the day prior to | | |
| 18), 909–914. | | | | | appointment | 0.001). | |
| | | | | | symptomatic | Detiente with entry 1 wight within 4 was be warded as a little to the | |
| | | | | | screening | Patients with only 1 visit within 4 weeks were more likely to not | |
| | | | | | | have been tested; 386/598 (64.5%) compared to patients with 2 or | |
| | | | | | | more visits;112/979 (11.4%), p< 0.001. The projected number of | |
| | | | | | | patients with undetected infection during the study period was 5. | |

| Gilner, J., Kansal, N., Biggio, J.R., Delaney, S., Grotegut, C.A., Hardy, E., Hughes, B.L. (2021). <u>Universal SARS-CoV-2</u> testing for obstetric inpatient units across the <u>United States</u> . <i>Clinical</i> <i>infectious diseases</i> , ciab955. | Nov 17, 2021 | Cross- sectional | Asymptomati c obstetric inpatients Nation-wide USA | n = 10,147 • 6,423 (63%)POC upon admission • 3,704 (30.3%) at admission Apr 3 – Jul 31, 2020 (wild-type) | Universal admission testing | During the study period, 124/10,147 (1.2%) asymptomatic people tested positive for COVID-19: Positivity rates varied by site, ranging from 0-3.2% Inpatient positivity rates were lower than in the surrounding communities; weighted positivity rate of 1.2% (95% CI = 0.5, 2.0) Asymptomatic positivity rates in obstetric inpatients units were positively correlated to rates in the surrounding communities of origin: Counties; r=0.782, p=0.003 States; r=0.708, p=0.007 | Moderate |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Merrick, B., Noronha, M., Batra, R., Douthwaite, S., Nebbia, G., Snell, L.B., Harrison, H.L. (2021). <u>Real-world deployment of</u> <u>lateral flow SARS-CoV-2</u> <u>antigen detection in the</u> <u>emergency department to</u> <u>provide rapid, accurate</u> <u>and safe diagnosis of</u> <u>COVID-19</u> . <i>Infection</i> <i>prevention in</i> <i>practice, 3</i> (4), 100186. | Nov 18, 2021 | Quasi- experime ntal | Acute care patients Emergency department London, United Kingdom | n=2,844 (1422 LFD, 1024 PCR) Jan 2-22, 2021 (Alpha VOC) | Reference period (1): PCR only (Dec 1 – Mar 30, 2021) Reference period (2): POC-r-PCR (Dec 15, 2020) Study period: • LFD (Jan 2-22, 2021) | During the reference period (1), the median turnaround time for RT-PCR testing was 3 hrs and 34 minutes (of a 4 hr emergency department (ED) performance target). This resulted in 1/3 patients leaving the ED without a confirmation diagnosis and 689 ED breaches (i.e., waited longer than the 4 hr performance target), 40/689 (5.8%) by patients waiting ward placement. During the reference period (2), point of care rapid-PCR testing decreased turnaround time (values NR) and resulted in 410/532 (77%) of patients leaving the ED with a confirmation diagnosis. ED breaches were reduced from 689 to 87, of those 20/87 (13.3%) by patients waiting ward placement. During the study period, 1422/2844 (50%) of ED patients had lateral flow device (LFD) testing and 1024/1422 (72%) had LFD with RT-PCR confirmation (within 48 hrs): LFD positive 288/1422 (20.3%) LFD negative: 1134/1422 (79.7%) based on disease prevalence of 34.7%; PPV = 97.7%; negative predictive value = 86.4%. LFD testing can be useful in meeting ED performance targets and reducing breaches. | High |

| Mortazavi, S.E., | Dec 31, | Cohort | Emergency | n=2,940 | ED patient pathway: | During the study period 1,866/2,940 (63.5%) were tested for | Moderate |
|-------------------------------|---------|--------|---------------|-------------------------------|------------------------------------------|-----------------------------------------------------------------------------------------|----------|
| Inghammar, M., | 2021 | | Departments | mean age: | Patients with | COVID-19 upon arrival at the emergency department (ED): | |
| Christiansen, C., Pesola, | | | patients (≥18 | 60.8 | suspected COVID-19 | 408/2,940 (13.9%) tested positive | PREPRINT |
| A., Stenkilsson, M., & | | | years) | (SD±20.8) | were transferred to | 1,458/2,940 (49.6%) tested negative | |
| Paulsson, M. (2021). <u>A</u> | | | | • 1497/2940 | units with increased | • 568/2,940(19%) had a positive test prior to admission to the ED | NOT PEER |
| cohort study of the effect | | | Skåne | (50.9%) | IPAC until results | 506/2,940 (17.2%) were not tested or test result was not | REVIEWED |
| of SARS-CoV-2 point of | | | University | women | were obtained. | recorded. | |
| care rapid RT-PCR at the | | | Hospital | | | | |
| Emergency Department | | | | Period 1: | Patients who tested | Compared to standard RT-PCR tests, use of rapid antigen tests for | |
| on targeted admission. | | | Lund, | Nov 13 – Dec 2, | negative remained | positive patients: | |
| Preprint. | | | Sweden | 2020 | in the ED until proper treatment | reduced the mean ED length of stay by 1.5 days (95% Cl = 0.3. 2.7); | |
| | | | | Period 2: | was delivered or | reduced admission to COVID-19 wards from 34.0/100 down to | |
| | | | | Dec 3 – Dec 22, | they were admitted | 14.7/100 admissions [(95% CI = 28.9, 40.5), (95% CI = 11.1, 19.1)]; | |
| | | | | 2020 | to a care ward (i.e., | | |
| | | | | | ICU, mixed- | Compared to standard RT-PCR tests, use of point-of-care-rapid- | |
| | | | | Period 3: | COVID/Internal | PCR for negative patients reduced transfers between hospital | |
| | | | | Dec 23, 2020 – | medicine ward) | wards in the first 5 days from 50.0 to 34.0/100 admission [(95% Cl | |
| | | | | Jan 12, 2021 | | = 45.0,55.0), (95% CI = 30.3,37.9)]. | |
| | | | | (Alpha VOC) | | | |
| O'Hara, L.M., Schrank, | Aug 20, | Cohort | Hospital HCW | n=5,135 | System policy | During the study period 5,135 HCW were PCR tested for COVID-19; | Moderate |
| G.M., Frisch, M., Hogan, | 2021 | | | | requires: | 342/5,135 (6.7%) tested positive: | |
| R., Deal, K. E., Harris, | | | Multi-site | Mar 1 – Aug 31, | staff use high-level | 301/342 (88%) were symptomatic; test positivity rate = 9.7% | |
| A.D., & Leekha, S. (2021). | | | healthcare | 2020 | PPE defined as | 41/342 (12%) were asymptomatic; test positivity rate = 2.0% | |
| Coronavirus disease 2019 | | | system | (wild-type) | respirator, eye | 2,787/5,135 (54.3%) did not report a known community or | |
| (COVID-19) symptoms, | | | | | protection, gloves, | work exposure | |
| patient contacts, | | | Maryland, | | and gowns | 2,348/5,135 (45.7%) had a known exposure | |
| <u>polymerase chain</u> | | | USA | | Extended use and | 928/2,348 (39.5%) were patient exposures | |
| reaction (PCR) positivity | | | | | decontamination of | 1,013/2,348 (43.1%) were colleague exposures | |
| and seropositivity among | | | | | N95 masks for | 218/2,348 (9.3%) were community exposures | |
| healthcare personnel in a | | | | | continued use | 189/2,348 (8.1%) were household exposures | |
| Maryland healthcare | | | | | Universal masking | | |
| system. Infection control | | | | | and eye protection | Compared to exposure from a positive patient, exposure in the | |
| and hospital | | | | | for all patient | home or community was associated with greater odds of | |
| epidemiology, 1–3. | | | | | contact | contracting COVID-19 for HCW: | |
| | | | | | Universal patient | Household exposure OR: 4.96 (95% Cl = 3.22, 7.64), p<0.0001 | |
| | | | | | admission testing | Community exposure OR: 2.86 (95% Cl = 1.79, 4.78), p<0.0001 | |
| | | | | | (beginning May 6, | Colleague (in hospital) exposure OR: 0.74 (95% CI = 0.49, 1.11) NS | |
| | | | | | 2020) | | |
| | | | 1 | 1 | | | |

| Kim, C.W. & Lee, Suk- | Cohort | Hospital, | n=495 | Universal admission | In Korea, all patients admitted for surgery first received a COVID- | High |
|--------------------------------|--------|--------------|----------------|---------------------|------------------------------------------------------------------------|------|
| Hwan. (2021). <u>Impact of</u> | | patients | | tesecondting | 19 test; admission could only proceed with a confirmed negative | |
| COVID-19 on the care of | | undergoing | pre-pandemic | | result. (If positive, patient transferred for treatment at a COVID-19- | |
| acute appendicitis: a | | laparoscopic | (Nov 2019) vs. | | designated facility.) | |
| single-center experience | | surgery for | pandemic (Nov | | | |
| in Korea. Annals of | | acute | 2020) groups | | The time between admission and surgery was longer in the | |
| Surgical Treatment and | | appendicitis | (wild-type, | | pandemic group than the pre-pandemic group (17.6 hours vs. 9 | |
| Research 101(4): 240-246. | | | Alpha VOC) | | hours, p <0.001). | |
| | | Korea | | | | |
| | | | | | Operating time was longer (p=0.014) and inflammation more | |
| | | | | | severe (50.9% vs. 60.9%, p=0.036) in the pandemic group; no | |
| | | | | | significant differences in postoperative complications or length of | |
| | | | | | stay. | |

*VOC: variant of concern; NR: not reported; RT-PCR: reverse transcriptase polymerase chain reaction; PCR: polymerase chain reaction; HCW: healthcare worker; LTC: long-term care; PPE: personal protective equipment; LFD: lateral flow device; ED: Emergency department; POC-r-PCR: point-of-care rapid-polymerase chain reaction; HSP: health surveillance screening; ICU: intensive care unit

References

Australian Government – Department of Health. (2022, June 10). <u>COVID-19 outbreaks in</u> <u>Australian residential aged care facilities</u>.

Benoni, R., Campagna, I., Panunzi, S., Varalta, M.S., Salandini, G., De Mattia, G., ... Bovo, C. (2021). <u>Estimating COVID-19 recovery time in a cohort of Italian healthcare workers who</u> <u>underwent surveillance swab testing</u>. *Public health*, *196*, 52–58.

Bertini, L., Bogen-Johnston, L., Middleton, J., Wood, W., Sadhwani, S., Forder, J., ... Cassell, J.A. (2021). <u>COVID-19 management in social care in England: a systematic review of changing policies and newspaper reported staff perspectives</u>. *Preprint*.

British Columbia Ministry of Health. (2022, March 23). <u>COVID-19: Viral testing guidelines for</u> <u>British Columbia</u>.

British Columbia Ministry of Health. (2022, March 18). <u>*Ministry of Health – Overview of visitors in long-term care and seniors' assisted living*.</u>

Calcaterra, L., Cesari, M., & Lim, W.S. (2022). <u>Long-Term Care Facilities (LTCFs) During the</u> <u>COVID-19 Pandemic-Lessons From the Asian Approach: A Narrative Review</u>. *Journal of the American Medical Directors Association*, *23*(3), 399–404.

Centres for Disease Control and Prevention. (2022, February 2). Infection Control Guidance.

Centers for Disease Control and Prevention. (2022, February 2). *Infection Control for Nursing <u>Homes</u>*.

Central Disaster Management Headquarters, Republic of Korea. (2022, May 26). <u>MOHW</u> <u>extends period of face-to-face contact visits to nursing hospitals and facilities</u>.

The Commissioner of the Federal Government for Culture and media. (n.d.). <u>What do you</u> <u>currently need to know about corona</u>.

Council on the Ageing. (2022, March 22). Industry code for visiting in aged care homes.

Department of Health of Northern Ireland. (2022, May 2). Visiting with care - A Pathway.

Diekmann, P.R., O'Neill, O.R., Floyd, E.R., Meinke, L.C., Lehman-Lane, J., Uzlik, R.M., & Stone McGaver, R. (2022). <u>Orthopedic Surgery in Ambulatory Surgery Centers During the COVID-19</u> <u>Pandemic: Low Incidence of Infection Among Patients, Surgeons, and Staff</u>. *Cureus*, *14*(4), e24247.

Fong, D., Mair, M.J., Lanthaler, F., Alber, M., & Mitterer, M. (2022). <u>Mobility as a driver of</u> <u>severe acute respiratory syndrome coronavirus 2 in cancer patients during the second</u> <u>coronavirus disease 2019 pandemic wave</u>. *International journal of cancer*, *150*(3), 431–439. Gascon, L., Fournier, I., Chiesa-Estomba, C., Russo, G., Fakhry, N., Lechien, J.R., ... Ayad, T. (2022). <u>Systematic review of international guidelines for head and neck oncology management in COVID-19 patients</u>. *European archives of oto-rhino-laryngology*, *279*(2), 907–943.

Geeraedts, F., Luttje, M., Visschedijk, J., van Hattem, M., Hasper, H.J., Kohnen, R., ... Al Naiemi, N. (2022). <u>Low-Threshold Testing for SARS-CoV-2 (COVID-19) in Long-Term Care</u> <u>Facilities Early in the First Pandemic Wave, the Twente Region, the Netherlands: A Possible</u> <u>Factor in Reducing Morbidity and Mortality</u>. *Journal of applied gerontology*, 7334648221093050.

Gilner, J., Kansal, N., Biggio, J.R., Delaney, S., Grotegut, C.A., Hardy, E., ... Hughes, B.L. (2021). <u>Universal SARS-CoV-2 testing for obstetric inpatient units across the United States</u>. *Clinical infectious diseases*, ciab955.

Giri, S., Chenn, L.M., & Romero-Ortuno, R. (2021). <u>Nursing homes during the COVID-19</u> <u>pandemic: a scoping review of challenges and responses</u>. *European geriatric medicine*, *12*(6), 1127–1136.

Government of Alberta. (2022, February). <u>*Questions & answers: COVID-19 requirements for licensed supportive living, long-term care and hospice settings*.</u>

Government of Alberta. (2022, April 29). <u>COVID-19 Prevalence Testing and Screening – DSL,</u> <u>LTC & Hospice</u>.

Government of Canada. (2022, July 5). *Infection prevention and control for COVID-19: Interim guidance for long-term care homes*.

Government of Manitoba. (2022, June 9). *Provincial guidance for COVID-19: A return to symptomatic testing infection prevention and control risk and response*.

Government of Prince Edward Island. (2022, June 7). COVID-19 close contacts.

The Government of the Hong Kong Special Administrative Region. (2022, April 30). <u>Government continues to provide free COVID-19 nucleic acid testing service for the elderly and</u> <u>targeted groups</u>.

Government of the Netherlands. (n.d.). <u>Getting tested for coronavirus by the GGD if you have</u> <u>symptoms</u>.

Government of Québec. (2022, May 4). *Instructions regarding clients' or residents' admission or return to a residence or rehabilitation centre*.

Government of Québec. (2022, May 30). Get a COVID-19 test.

Hashim, N., Mahdy, Z.A., Abdul Rahman, R., Kalok, A., & Sutan, R. (2022). <u>Universal Testing</u> <u>Policy for COVID-19 in Pregnancy: A Systematic Review</u>. *Frontiers in public health*, *10*, 588269.

Health PEI. (2022, January 5). Fast pass priority COVID-19 testing available for staff.

Israel Ministry of Health. (2022, June 24). *When to be tested*.

Kim, C.W. & Lee, Suk-Hwan. (2021). <u>Impact of COVID-19 on the care of acute appendicitis: a</u> <u>single-center experience in Korea</u>. *Annals of Surgical Treatment and Research 101*(4): 240-246.

Liu, K.Y., Kulatilake, A., Kalafatis, C., Smith, G., King, J.D., Serra-Mestres, J., ... Livingston, G. (2022). Infection control and the prevalence, management and outcomes of SARS-CoV-2 infections in mental health wards in London, UK: lessons learned from wave 1 to wave 2. *BJPsych open*, *8*(2), e63.

Mei, Y., Guo, X., Chen, Z., & Chen, Y. (2022). <u>An effective mechanism for the early detection</u> and containment of healthcare worker infections in the setting of the COVID-19 pandemic: a systematic review and meta-synthesis. *Int J Environ Res Public Health, 19*(10), 5943.

Merrick, B., Noronha, M., Batra, R., Douthwaite, S., Nebbia, G., Snell, L.B., ... Harrison, H.L. (2021). <u>Real-world deployment of lateral flow SARS-CoV-2 antigen detection in the emergency</u> <u>department to provide rapid, accurate and safe diagnosis of COVID-19</u>. *Infection prevention in practice, 3*(4), 100186.

Ministry of Health Singapore. (2022, April 25). *Further easing of measures for in-person visits to hospitals and residential care homes*.

Ministry of Health Singapore. (2022, February 16). <u>*Resetting our measures to live with the omicron variant*</u>.

Möckel, M., Bolanaki, M., Hofmann, J., Stein, A., Hitzek, J., Holert, F., ... Slagman, A. (2022). SARS-CoV-2 screening in patients in need of urgent inpatient treatment in the Emergency Department (ED) by digitally integrated point-of-care PCR: a clinical cohort study. *Diagnostic microbiology and infectious disease*, *102*(4), 115637.

Mortazavi, S.E., Inghammar, M., Christiansen, C., Pesola, A., Stenkilsson, M., & Paulsson, M. (2021). <u>A cohort study of the effect of SARS-CoV-2 point of care rapid RT-PCR at the Emergency Department on targeted admission</u>. *Preprint*.

Moyer, S., Aktay, S., & Blanchard, S. (2022). <u>The COVID-19 Pandemic Impact on Pediatric</u> <u>Endoscopies in a Single Center</u>. *Global pediatric health*, *9*, 2333794X221100948.

National Health Service. (2022, July 4). Who can get a free NHS coronavirus (COVID-19) test.

National Health Service Scotland. (2022, June 16). *Testing*.

Nationalt Kommunikations Partnerskab COVID-19. (2022, July 5). Rules and Regulations.

Neil-Sztramko, S.E., Belita, E., Traynor, R.L., Clark, E., Hagerman, L., & Dobbins, M. (2021). <u>Methods to support evidence-informed decision-making in the midst of COVID-19: creation and</u> <u>evolution of a rapid review service from the National Collaborating Centre for Methods and</u> <u>Tools</u>. *BMC Medical Research Methodology 21*(231).

New Brunswick Department of Social Development. (2022, July). <u>Living with COVID:</u> <u>Management of COVID-19 for New Brunswick long term care homes</u>.

New Zealand Ministry of Health. (2022, June 23). Free testing for specific groups.

New Zealand Ministry of Health. (2022, May 17). *Testing guidance*.

Northwest Territories Health and Social Services Authority. (2022, April 25). <u>COVID-19 public</u> <u>testing guidance</u>.

O'Hara, L.M., Schrank, G.M., Frisch, M., Hogan, R., Deal, K. E., Harris, A.D., & Leekha, S. (2021). <u>Coronavirus disease 2019 (COVID-19) symptoms, patient contacts, polymerase chain reaction</u> (PCR) positivity and seropositivity among healthcare personnel in a Maryland healthcare <u>system</u>. *Infection control and hospital epidemiology*, 1–3.

Ontario Ministry of Health. (2022, June 11). COVID-19 guidance: Acute care.

Ontario Ministry of Health. (2022, June 11). <u>COVID-19 guidance: Long-term care homes and</u> <u>retirement homes for public health units</u>.

Government of Ontario. (2022, June 28). <u>COVID-19 guidance document for long-term care</u> <u>homes in Ontario</u>.

The Public Health Agency of Sweden. (2022, March 3). Testing for COVID-19.

Public Health Scotland. (2022, May 31). <u>COVID-19: Information and guidance for care home</u> <u>settings</u>.

Rhee, C., Baker, M.A., & Klompas, M. (2022). <u>Survey of coronavirus disease 2019 (COVID-19)</u> infection control policies at leading US academic hospitals in the context of the initial pandemic surge of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron variant. *Infection control and hospital epidemiology*, 1–7.

Saskatchewan Health Authority. (2022, June 20). <u>Saskatchewan Health Authority COVID-19</u> <u>outbreak guidance for long term care homes</u>.

Schünemann, H., Brożek, J., Guyatt, G., & Oxman, A. (2013). *Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach*.

Swiss Confederation. (2022, June 14). <u>*Coronavirus: Protect yourself and others*</u>. UK Health Security Agency. (2022, May 9). <u>*COVID-19 testing in adult social care*</u>.

Vardavas, C., Zisis, K., Nikitara, K., Lagou, I., Aslanoglou, K., Athanasakis, K., ... Suk, J.E. (2022). <u>The cost of the COVID-19 pandemic vs the cost-effectiveness of mitigation strategies in the EU/UK/EEA and OECD countries: a systematic review</u>. *Preprint*.

World Health Organization. (2022, March 9). <u>*Country & technical guidance – Coronavirus</u>* <u>*disease (COVID-19)*</u>. Technical Guidance Publications.</u>

Yukon Communicable Disease Control. (2022, June 8). <u>*COVID-19 testing regulations –</u>* <u>*Whitehorse and rural Yukon*</u>.</u>